December 20, 2022
C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform: C-Path announced that the European Medicines Agency (EMA) has issued a letter of support for the Critical Path for Parkinson’s (CPP) Consortium’s Model-based Clinical Trial Simulation Platform to Optimize Design of Efficacy Evaluation Studies in Parkinson’s Disease (PD).
